DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for substance withdrawal syndrome — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSubstance withdrawal syndrome maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for substance withdrawal syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adrenoceptor alpha 2C (ADRA2C) — ADRA2C is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 8~{a}~{r},12~{a}~{s},13~{a}~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6KUW · 2.8 Å · ligand (8~{a}~{R},12~{a}~{S},13~{a}~{R})-12-ethylsulfonyl-3-methoxy-5,6,8,8~{a},9,10,11,12~{a},13,13~{a}-decahydroisoquinolino[2,1-g][1,6]naphthyridine (E33). Experimental structure, not a prediction.
What the evidence adds up to
The dependence syndrome concept, tested in 1987 on alcoholic and opiate addicts, predicted reinstatement of alcohol use well but did not predict reinstatement in opiate users as consistently. The authors concluded the concept needed better operational measures and more rigorous testing, especially in drug-user samples. A 2000 review of alcohol withdrawal genetics described it as a heterogeneous syndrome caused by multiple genes, each contributing modestly, and noted methodological limitations in candidate-gene association studies. A 2024 review of visceral systems in substance use disorders argued that chronic intoxication provokes somatic diseases and that common biochemical pathways between addiction and comorbidities might be a basis for drug repurposing, but offered no clinical data.
Two narrative reviews from 2021 and 2022 on withdrawal management stated that alcohol, opioid, and stimulant withdrawal syndromes can be life-threatening if untreated and that patients presenting with withdrawal should be offered a long-term, holistic approach including psychosocial interventions and evidence-based pharmacotherapies. Both reviews described recent advances but also challenges in clinical care, and neither reported new trial results or specific drug outcomes. A 2024 rat study of cocaine withdrawal versus extinction in the nucleus accumbens found that home-cage withdrawal maintained drug seeking in the previous drug context, extinction training reduced it, and withdrawal involving repetitive exposure to the previous drug context increased drug-seeking behaviour. Transcriptomic analysis of rat nucleus accumbens subregions revealed gene expression patterns specific to each condition, and comparison with human cocaine use disorder tissue showed conserved gene signatures, particularly in rats repetitively exposed to the drug context. The study identified potential molecular mechanisms but did not test any intervention.
No abstract reported a randomised trial, a repurposed drug, or a specific pharmacological outcome for withdrawal symptoms in humans. What is missing is funding for clinical trials that test candidate compounds identified from the molecular pathways discussed, trial designs that account for the heterogeneity of withdrawal syndromes and patient stratification by genetic or dependence-severity markers, and studies that move beyond rodent transcriptomics to human proof-of-concept.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Critical Care · 2018 · 71 citations · open access
Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA-Ar Protocol
AbstractBACKGROUND: Benzodiazepine-based therapy for alcohol withdrawal is associated with agitation and respiratory depression. Treatment can be complicated by a need for adjunctive therapy to control these symptoms and in patients requiring mechanical ventilation. Strong evidence for the effectiveness of alternative treatment modalities is lacking, despite the availability of promising pharmacological agents such as phenobarbital. OBJECTIVE: To compare the standard of care for the treatment of alcohol withdrawal-a symptom-triggered benzodiazepine protocol used in conjunction with the revised Clinical Institute Withdrawal Assessment of Alcohol (CIWA-Ar) scale-with a phenobarbital protocol. METHODS: Retrospective cohort study conducted from January 2016 through June 2017 at a 42-bed medical intensive care unit in a private teaching hospital in Nashville, Tennessee. The primary outcome was intensive care unit length of stay. Secondary outcomes included hospital length of stay, incidence of invasive mechanical ventilation, and use of adjunctive pharmacotherapy. RESULTS: = .002). CONCLUSION: A phenobarbital protocol for the treatment of alcohol withdrawal is an effective alternative to the standard-of-care protocol of symptom-triggered benzodiazepine therapy.
British Journal of Addiction · 1987 · 65 citations
The Dependence Syndrome Concept as a Psychological Theory of Relapse Behaviour: an empirical evaluation of alcoholic and opiate addicts
AbstractSummary This paper examines the drug dependence syndrome (DSS) concept as a psychological theory of relapse to alcohol or opiate use following a period of abstinence from these substances. The results of several empirical studies of relapse in alcoholics and opiate users are described. Measures of the alcohol dependence syndrome provided good prediction of reinstatement in alcoholics, but severity of drug dependence did not predict reinstatement as consistently in opiate users. It is concluded that while the DDS concept may have merit as a psychological explanation of reinstatement, it should be subjected to a more rigorous program of research aimed at better operational measures and more intensive hypothesis testing, especially in samples of drug users.
AbstractAlcohol withdrawal is a clinically and etiologically heterogeneous syndrome caused by a complex interaction of environmental (e.g., amount of ethanol) and genetic factors. Multiple genes are considered to be involved in various components of the syndrome, each of them contributing only modestly to withdrawal vulnerability. Association studies using candidate genes of the dopamine, serotonin, gabaergic and opioidergic systems are reviewed and methodological limitations are discussed.
Biochemistry (Moscow) · 2024 · 6 citations · open access
Contribution of Visceral Systems to the Development of Substance Use Disorders: Translational Aspects of Interaction between Central and Peripheral Mechanisms
AbstractSubstance use disorders are associated with structural and functional changes in the neuroendocrine, neuromediator, and neuromodulator systems in brain areas involved in the reward and stress response circuits. Chronic intoxication provokes emergence of somatic diseases and aggravates existing pathologies. Substance use disorders and somatic diseases often exacerbate the clinical courses of each other. Elucidation of biochemical pathways common for comorbidities may serve as a basis for the development of new effective pharmacotherapy agents, as well as drug repurposing. Here, we discussed molecular mechanisms underlying integration of visceral systems into the central mechanisms of drug dependence.
Open Collections · 2022 · 0 citations · open access
Modernizing Withdrawal Management Services
AbstractAlcohol, opioid, and stimulant withdrawal syndromes are serious clinical presentations, some of which can be life-threatening if untreated. Patients presenting with withdrawal syndromes offer an important opportunity for healthcare providers to ally in deciding the most appropriate treatment setting, safely treating withdrawal symptoms, preventing potentially severe medical complications, and facilitating a transition to longer-term low-barrier substance use care including, where available, psychosocial interventions, evidence-based pharmacotherapies, and referrals for other community-based or specialist-led services. Given that substance use disorders are chronic biopsychosocial disorders commonly characterized by periods of relapse and remission, patients presenting in substance withdrawal deserve a long term and holistic approach to management that cannot be simply achieved in short-term withdrawal management siloed and separate from a continuum of care. This narrative review of withdrawal management literature describes recent advances in clinical care for patients in withdrawal from alcohol, opioids, and stimulants.
The Canadian Journal of Addiction · 2021 · 0 citations
Modernizing Withdrawal Management Services
AbstractABSTRACT Alcohol, opioid, and stimulant withdrawal syndromes are serious clinical presentations, some of which can be life-threatening if untreated. Patients presenting with withdrawal syndromes offer an important opportunity for healthcare providers to ally in deciding the most appropriate treatment setting, safely treating withdrawal symptoms, preventing potentially severe medical complications, and facilitating a transition to longer-term low-barrier substance use care including, where available, psychosocial interventions, evidence-based pharmacotherapies, and referrals for primary care-based or specialist-led services. Given that substance use disorders are chronic biopsychosocial disorders commonly characterized by periods of relapse and remission, patients presenting in substance withdrawal deserve a long-term and holistic approach to management that cannot be simply achieved in short-term withdrawal management siloed and separate from a continuum of ongoing substance use care. With this in mind, this narrative review of withdrawal management literature describes recent advances and challenges in clinical care for patients in withdrawal from alcohol, opioids, and stimulants. Les syndromes de sevrage liés à l’alcool, aux opioïdes et aux stimulants sont des manifestations cliniques graves, dont certaines peuvent mettre la vie en danger si elles ne sont pas traitées. Les patients présentant des syndromes de sevrage offrent aux fournisseurs de soins de santé une occasion importante de s’allier pour décider du cadre de traitement le plus approprié, traiter en toute sécurité les symptômes de sevrage, prévenir les complications médicales potentiellement graves et faciliter la transition vers des soins de consommation de substances à faible barrière à long terme, y compris, lorsque disponibles, interventions psychosociales, pharmacothérapies fondées sur des données probantes et aiguillage vers des services de soins primaires ou dirigés par des spécialistes. Étant donné que les troubles liés à l’usage de substances sont des troubles biopsychosociaux chroniques généralement caractérisés par des périodes de rechute et de rémission, les patients se présentant en sevrage de substances méritent une approche à long terme et holistique de la prise en charge qui ne peut être simplement réalisée dans une gestion du sevrage à court terme cloisonnée et séparée d’un continuum des soins continus liés à l’usage de substances. Dans cet esprit, cette revue narrative de la littérature sur la gestion du sevrage décrit les progrès récents et les défis dans les soins cliniques pour les patients en sevrage d’alcool, d’opioïdes et de stimulants.
bioRxiv (Cold Spring Harbor Laboratory) · 2024 · 0 citations · open access
Transcriptional characterization of cocaine withdrawal versus extinction within nucleus accumbens
AbstractSubstance use disorder is characterized by a maladaptive imbalance wherein drug seeking persists despite negative consequences or drug unavailability. This imbalance correlates with neurobiological alterations some of which are amplified during forced abstinence, thereby compromising the capacity of extinction-based approaches to prevent relapse. Cocaine use disorder (CUD) exemplifies this phenomenon in which neurobiological modifications hijack brain reward regions such as the nucleus accumbens (NAc) to manifest craving and withdrawal-like symptoms. While increasing evidence links transcriptional changes in the NAc to specific phases of addiction, genome-wide changes in gene expression during withdrawal vs. extinction (WD/Ext) have not been examined in a context- and NAc-subregion-specific manner. Here, we used cocaine self-administration (SA) in rats combined with RNA-sequencing (RNA-seq) of NAc subregions (core and shell) to transcriptionally profile the impact of experiencing withdrawal in the home cage or in the previous drug context or experiencing extinction training. As expected, home-cage withdrawal maintained drug seeking in the previous drug context, whereas extinction training reduced it. By contrast, withdrawal involving repetitive exposure to the previous drug context increased drug-seeking behavior. Bioinformatic analyses of RNA-seq data revealed gene expression patterns, networks, motifs, and biological functions specific to these behavioral conditions and NAc subregions. Comparing transcriptomic analysis of the NAc of patients with CUD highlighted conserved gene signatures, especially with rats that were repetitively exposed to the previous drug context. Collectively, these behavioral and transcriptional correlates of several withdrawal-extinction settings reveal fundamental and translational information about potential molecular mechanisms to attenuate drug-associated memories.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
